This review examines the occurrence and predictors of rebound regrowth following MAPK inhibitor treatment discontinuation in pediatric low-grade gliomas.
Systematic literature review according to PRISMA 2020 guidelines
Included clinical trials, cohort studies, and case reports/series involving patients aged 0-25 years
RR was defined as radiological progression within 6 months after treatment cessation.
Among ten studies with ≥10 patients, RR occurred in at least 23 of 131 evaluable individuals.
Most RR events were detected early post-discontinuation and were clinically asymptomatic.
RR was most common in tumors with the BRAF V600E variant, with most patients showing a positive response to MAPK inhibitor rechallenge.